Lantern Pharma (NASDAQ: LTRN): Investing in Tomorrow's Cures: Unveiling the Power of AI Drug Development Platforms

Lantern Pharma (Nasdaq: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern Pharma has accelerated the development of its growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, Lantern Pharma’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program. Learn more at LTRNinfo.com. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Lantern Pharma (LTRN) is a client of RedChip Companies, Inc. LTRN agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2023, and 2500 shares of Rule 144 stock for six months of RedChip investor awareness services. The shares have been registered and RedChip intends to sell its shares. LTRN also agreed to pay RedChip a one-hundred-four-thousand dollar fee for a six week national TV ad campaign scheduled to air weekdays from February 26 through April 15, 2024.   For full disclosure, visit RedChip.com/disclosures.